entertainment -WSS

entertainment

author：fashion 2025-10-01 15:30:41 - browse：46214

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

focus

WSS

Amylyx ALS drug failure raises questions and concerns

A deep dive into Applied Therapeutics’ data, and questions on Cassava

NEJM study link tiny plastics in blood vessels to heart problems

The problem with charging patients to message their doctors

STAT Summit: How a Chicago ER doctor tackles gun violence

NIH confirmation hearing shows politicization of research

leisure time

entertainment

hotspot

Psychedelics group wrestles with new pharma identity

CEOs share strategies for surviving biotech slump

As demand for Covid shots wanes, Moderna seeks its next success

STAT Readout Newsletter: Today's biggest biotech updates

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Anesthesiologist group: stop taking Ozempic before surgery

CEOs share strategies for surviving biotech slump

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Air quality improving but still lags in Black, Hispanic communities

focus

A deep dive into Applied Therapeutics’ data, and questions on Cassava

The EU Joint Clinical Assessment needs to live up to its promise

First medicine developed to treat MASH expected to be approved soon

Headspace, Meta partner to launch VR meditation app for Quest

UnitedHealth quietly bought dozens of outpatient centers

STAT Summit: GSK CEO on pharma giant's new direction

hotspot

focus

focus

leisure time